Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2025)

Journey Medical's Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $94.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 17.88% year-over-year to $94.6 million, compared with a TTM value of $345.9 million through Dec 2025, up 25.31%, and an annual FY2025 reading of $94.6 million, up 17.88% over the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $94.6 million at Journey Medical, up from $85.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $120.9 million in Q1 2022, with the low at $64.0 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $86.9 million, with a median of $85.1 million recorded in 2025.
  • Year-over-year, Liabilities and Shareholders Equity surged 87.42% in 2021 and then tumbled 39.05% in 2023.
  • Tracing DERM's Liabilities and Shareholders Equity over 5 years: stood at $97.3 million in 2021, then increased by 8.1% to $105.2 million in 2022, then decreased by 26.92% to $76.8 million in 2023, then grew by 4.41% to $80.2 million in 2024, then grew by 17.88% to $94.6 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Liabilities and Shareholders Equity are $94.6 million (Q4 2025), $85.2 million (Q3 2025), and $81.2 million (Q2 2025).